Long-term polymer residue in the coronary milieu is a consequence of current drug-eluting stent (DES) therapy and has been implicated in late adverse events. We developed a novel polymer-free rapamycin-and probucol-eluting stent (Dual-DES) and compared its efficacy against commercially available permanent polymer-based sirolimuseluting (SES; Cypher) and zotarolimus-eluting (ZES; Endeavor) stents.
Background
Drug-eluting stent (DES) treatment has impacted greatly on patient outcomes following percutaneous coronary intervention, reducing the need for repeat intervention by 50-70% in comparison with bare metal stent implantation. 1 Heretofore, all stents approved for clinical use by the United States Food and Drug Administration have incorporated a permanent polymer in their design in order to delay the release of active compound from the stent platform and thereby enhance its anti-restenotic efficacy. Concerns have been raised however that the persistence of durable polymer after its functional role has been served may be associated with deleterious effects. 2, 3 Polymer residue in the coronary milieu may promote an ongoing active inflammatory response at the vessel-wall level and presents both a potential nidus for late thrombotic stent occlusion as well as a stimulus for ongoing neointimal overgrowth. 4 -6 The introduction of DES therapy has resulted in an update of guideline recommendations concerning dual antiplatelet therapy duration after stenting on both sides of the Atlantic. 7, 8 The potential benefit of a prolongation of clopidogrel therapy in terms of a reduction in ischaemic events might be outweighed by the consequent increased bleeding risks. 9 We have previously reported our experiences with the ISAR (Individualizable drug-eluting Stent system to Abrogate Restenosis) stent, demonstrating that an equivalent anti-restenotic performance to that of the Taxus stent may be effected without resort to durable polymer, by the incorporation of micropores-which enhance drug release kinetics-into a metal stent backbone. 10 -12 Subsequently, however, this platform failed to show non-inferiority when compared with the permanent polymer Cypher stent, which is arguably the current DES gold standard in terms of antirestenotic efficacy. 13 One option to further enhance the antirestenotic performance of a polymer-free platform is the incorporation of a second active agent targeted at another element of the restenotic response cascade. Previous experience with a dual oestrogen-and rapamycin-eluting platform 14 and a dual pimecrolimus-and paclitaxel-eluting device 15 did not result in enhanced performance efficacy. Probucol is a potent liposoluble antioxidant which has proven effects-both in animal models and in clinical trials-in reducing neointimal hyperplasia, the dominant cause of in-stent restenosis. 16 -18 Its successful inclusion into a DES model has thus far not been reported. The latest iteration of the ISAR stent incorporates rapamycin and probucol on a microporous stent backbone without the use of polymer (Dual-DES). We sought to compare its anti-restenotic efficacy against both the permanent polymer sirolimus-eluting stent (SES; Cypher) and the permanent polymer zotarolimuseluting stent (ZES; Endeavor)-against which an ISAR platform stent has not previously been tested.
Methods Patients
Patients were enrolled between March 2006 and July 2007 at the two participating centres: the Deutsches Herzzentrum and the Medizinische Klinik I, Klinikum rechts der Isar, Munich, Germany. Patients older than age 18 with ischaemic symptoms or evidence of myocardial ischaemia in the presence of 50% de novo stenosis located in native coronary vessels were eligible for inclusion provided that written informed consent for participation in the study was obtained from the patient or the patient's legally authorized representative. Exclusion criteria were target lesion location in the left main stem or bypass graft; in-stent restenosis; cardiogenic shock; malignancies or other co-morbid conditions (for example, severe liver, renal, and pancreatic disease) with life expectancy ,1 year or that may result in protocol non-compliance; known allergy to the study medications: aspirin, clopidogrel, zotarolimus, rapamycin, stainless steel, or cobalt alloy; pregnancy; or previous enrolment in this trial. The study was conducted in accordance with the provisions of the Declaration of Helsinki and with the International Conference on Harmonization Good Clinical Practices, and the protocol approval was obtained from the medical Ethics Committee/Institutional Review Board at each participating centre.
Device description
Patients were randomized to treatment with one of three DES devices. The primary active compound in all three stents is rapamycin-based. These compounds inhibit neointimal growth through disruption of cell cycle progression via inactivation of the mammalian target of rapamycin. The Cypher stent (SES) comprises a stainless steel backbone, a composite PEVA/PMBA permanent polymer, and rapamycin (sirolimus) as the active compound. The Dual-DES stent platform utilizes a thin strut (87 mm) sand-blasted microporous, 316L stainless steel stent backbone. A detailed description for creating the micropores along with its rationale has been reported previously. 10 The active compounds are rapamycin (0.7%) and probucol (0.7%), which are dissolved in solution in a 1:1 ratio, combined with a shellac resin (0.07%), and applied to the stent surface in a single coating process; no polymer is employed. The coating process is fully sterile and takes between 3 and 8 min depending on stent length. 10 The distribution concentration of rapamycin is 120 mg/cm 2 stent and of probucol is 100 mg/cm 2 .
Determination of dosages is performed by drug elution in 1.5 mL ethanol 100% overnight at 48C. Rapamycin and probucol amounts are then quantified by UV-range spectroscopy at 280 and 254 nm, respectively. The integrity of the distribution of drug coating is verified by light microscopic examination. Release kinetics for both drugs is shown in Figure 1 . The reproducibility of drug-loading dosages, distribution, and elution kinetics is verified by repeated examination of multiple stent samples selected at random. Shellac resin is a biocompatible resin widely used in the coating of medical tablets; its release kinetics are similar to those of both active drugs. The inclusion of resin allows for improved adherence of the drug mixture to the stent surface and enhances the structural integrity of the coating. No traces of rapamycin, probucol, or resin are observable beyond 6-8 weeks. Details of drug concentrations in vascular tissue following Dual-DES implantation in an animal model are reported elsewehere. 19 The Endeavor stent (ZES) comprises a cobalt chromium stent with a permanent, phosphorylcholine-based polymer. The active compound is zotarolimus-a close structural analogue of rapamycin which differs only in the presence of a tetrazole group at position 42, a modification responsible for reducing the terminal half-life of the compound and, in theory, limiting non-target organ side effects. Detailed elution characteristics of the SES and ZES stents are reported elsewhere.
20,21
Randomization, interventions, and adjunctive therapy
In each participating centre, allocation to treatment was by means of sealed, opaque envelopes containing a computer-generated sequence; this was performed immediately after decision to proceed with percutaneous intervention. Patients who met all of the inclusion criteria and none of the exclusion criteria were randomized in the order that they qualified. Patients were allocated to each of the three treatment groups in equal proportions. The treatment groups were studied concurrently. Time zero was defined as the time of randomization. Patients were considered enrolled in the study and eligible for the final intention-to-treat analysis at the time of randomization. The same randomly assigned stent had to be implanted in all lesions in those patients who required stenting in multiple lesions, and the use of more than one stent per lesion was also allowed. An oral loading dose of 600 mg clopidogrel was administered to all patients at least 2 h prior to the intervention, regardless of whether the patient was taking clopidogrel prior to admission. Immediately after the decision to perform the intervention, patients were given 500 mg aspirin intravenously or orally (if they had not received it within the prior 12 h) and intra-arterial or intravenous heparin up to a total amount of 140 U/kg body weight. Glycoprotein IIb/IIIa inhibitors were given at the discretion of the operators. After the intervention, all patients received 200 mg/day aspirin indefinitely, clopidogrel 150 mg for the first 3 days (or until discharge) followed by 75 mg/day for at least 6 months, and other cardiac medications according to the judgement of the patient's physician.
Follow-up protocol
Blood samples were drawn every 8 h for the first 24 h after randomization and daily thereafter for the determination of cardiac markers (CK, CK-MB). Daily recordings of ECG were performed until discharge. All patients were evaluated at 1 month and 12 months either by phone or office visit. Repeat coronary angiography was scheduled for 6 -8 months. Relevant data were collected and entered into a specialized computer database by the personnel of the Clinical Data Management Center. An events committee (see Appendix) operated completely independent of trial design and conduct, working within the framework of definitions pre-specified in the trial protocol, and fully blinded to the primary outcomes of the trial and the randomized treatment for any adjudicated patient.
Study endpoints and definitions
Baseline, post-procedural, and follow-up coronary angiograms were digitally recorded and assessed off-line in the quantitative angiographic core laboratory (ISAR Centre, Munich, Germany) with an automated edge-detection system (CMS version 7.1, Medis Medical Imaging Systems, Leiden, The Netherlands) by two independent experienced operators blinded to the treatment allocation. All measurements were performed on cineangiograms recorded after the intracoronary administration of nitroglycerin using the same single worst-view projection at all times. The contrast-filled non-tapered catheter tip was used for calibration. Quantitative analysis was performed on both the 'in-stent' and 'in-segment' area (including the stented segment, as well as both 5 mm margins proximal and distal to the stent). Qualitative morphological lesion characteristics were characterized by standard criteria. The primary endpoint of the study was the incidence of binary angiographic restenosis at 6 -8 month follow-up angiography-measured by quantitative coronary angiography-in the in-segment area. Secondary endpoints were the need for target lesion revascularization (TLR) (defined as any revascularization procedure involving the target lesion owing to luminal re-narrowing in the presence of symptoms or objective signs of ischaemia); the combined incidence of death or myocardial infarction; in-stent late luminal loss; and the incidence of stent thrombosis. Remote target vessel revascularization was defined as any revascularization of the target vessel not involving the target lesion. The diagnosis of myocardial infarction required the presence of new Q waves on the ECG and/ or elevation of creatinine kinase or its MB isoform to at least three times the upper limit of normal in no fewer than two blood samples. Stent thrombosis was classified according to Academic Research Consortium criteria. 22 Sample size calculation and statistical methods ISAR-TEST-2 was a prospective, randomized trial designed to compare the anti-restenotic efficacies of the three limus agent stents. To calculate sample size, we followed the method for detection of differences in proportions appropriate for two or more groups as described by Lachlin. 23 For a power of 80% and an a-level of 0.05, for each group 245 patients were estimated to be needed to detect a difference in proportions characterized by a variance of proportions of 0.14% and an average proportion of 11.7%; the latter two parameters were generated by assuming restenosis rates of 7, 12, and 16% for SES, 24 ZES, 21 and Dual-DES, 11, 13 respectively. Expecting that up to 20 -25% of the patients would not attend for follow-up angiography, 1002 patients were planned to be enrolled (334 patients per group). Analyses relative to sample size calculations were performed with nQuery Advisor, version 4.0 (Statistical Solutions, Cork, Ireland). In the event of a significant difference in the primary analysis, two pre-specified superiority analyses were planned to be performed, comparing the performance of Dual-DES with that of the SES and ZES. To account for multiple testing, a P-value ,0.025 was considered statistically significant according to the Bonferroni method. 25 All analyses were planned on the basis of the intention-to-treat principle, i.e. analyses were based on treatment groups as randomized. Regarding the possible influence of interlesion dependence in patients with more than one treated lesion, we performed an additional sensitivity analysis on the basis of the random selection of a single treated lesion per patient. Baseline descriptive statistics are presented as frequencies and percentages for categorical variables and means + standard deviation or median (inter-quartile range) for continuous variables. Differences across groups were checked for significance with analysis of variance (continuous data) or contingency table analysis (categorical variables). Intergroup outcome comparisons were assessed using Student's t-test (continuous data) and x 2 or Fisher's exact test (where expected cell value was ,5) for categorical variables. Survival and event-free status were assessed using the methods of Kaplan-Meier. Statistical software S-PLUS, version 4.5 (S-PLUS, Insightful Corp., Seattle, WA, USA), was used for all analyses.
Results

Baseline characteristics and procedural results
Study patient flow chart is shown in Figure 2 . A total of 1007 patients were enrolled in this study: 335 patients received the permanent-polymer SES, 333 were treated with the Dual-DES, and 339 received a permanent-polymer ZES. Baseline clinical characteristics are shown in Table 1 and were well matched across all three treatment groups. In all, 1266 lesions were treated (mean number of lesions treated per patient 1.3 + 0.5). Procedural characteristics are shown in Table 2 . Implantation of the assigned stent was successful in all patients. There were no differences in rates of procedural complications: at 30 days, the rate of death or myocardial infarction was similar across the treatment groups [11 (3.3%) with SES, 13 (3.9%) Dual-DES, 13 (3.8%) ZES; P ¼ 0.89].
Angiographic and clinical outcomes
Follow-up angiographic data were available for 828 (82.2%) patients with no significant differences in follow-up rate across treatment groups (P ¼ 0.41). The median (inter-quartile range) interval to repeat coronary angiography was 197 (185 -211) days. Clinical follow-up data at 1 year were available for all patients. Angiographic follow-up results are shown in Table 3 . In terms of binary angiographic restenosis-the primary endpoint of the study-there was a significant difference across the treatment groups (P ¼ 0.003). The incidence of angiographic restenosis in the Dual-DES group (11.0%) was significantly lower than that in the ZES group (19.3%; P ¼ 0.002) but similar to that in the SES group (12.0%; P ¼ 0.68) (Figure 3) .
In-stent late luminal loss was significantly different across the treatment groups (P , 0.001). The rate of late loss observed with Dual-DES (0.23 + 0.50 mm) was significantly lower than that observed with the ZES (0.58 + 0.55 mm; P , 0.001) and similar to that of the SES (0.24 + 0.51 mm; P ¼ 0.78). We also performed an additional sensitivity analysis-by randomly selecting a single treated lesion per patient-and found that this did not substantially alter our results.
There was also a significant difference in clinical restenosis across the treatment groups (P , 0.001; (Figures 3 and 4) .
No differences were observed between stent groups in terms of death, myocardial infarction, or stent thrombosis ( Table 4) . There were eight episodes of definite stent thrombosis in total-three in the Dual-DES group (at 2.5 h, 8 and 24 days); two in the ZES group (at 10 and 14 days); and three in the SES group (at 10, 96, and 173 days).
No significant differences in the duration of clopidogrel therapy were observed between the groups; duration of therapy was at least 1 year in 79.5, 78.4, and 76.1% of patients treated with the SES, Dual-DES, and ZES, respectively; 6 months to 1 year in 15.2, 18.9, and 19.7%, respectively; and shorter than 6 months in the remainder of cases.
Discussion
To our knowledge, this is the first report of the successful incorporation of a double-active drug system into a DES platform. The main finding of this randomized clinical trial was that the described novel rapamycin-and probucol-eluting Dual-DES demonstrated an antirestenotic efficacy comparable with that of the SES and superior to that of the zotarolimus-stent. The importance of these results lies in the achievement of an excellent performance efficacy-in keeping with that of the current gold standard DES-utilizing a stent platform which is devoid of polymer. Whether the absence of durable polymer from the coronary milieu over the mid-to long-term translates into significant differences in clinical outcomes will require further investigation. However, the potential safety implications in terms of a reduced incidence of late adverse events and an obviation of the need for prolonged thienopyridine therapy (and its attendant bleeding risks) are inherently attractive. Furthermore, the study population included a large sample size with complex lesion and patient characteristics and displays a performance that may be expected to transfer to real clinical practice.
There is significant concern regarding the incidence of late adverse events following DES implantation. Considerable debate has centred on the occurrence of late thrombotic stent occlusion-often though not invariably after the discontinuation of the clopidogrel component of dual anti-platelet therapy. 22,26 -29 This has resulted in a revision of guideline recommendations concerning the duration of dual antiplatelet therapy. 7, 8 The consequences of an increasing duration of aggressive antiplatelet therapy on patient morbidity-in terms of bleeding events or surgical procedure deferral-and perhaps mortality remain largely unmeasured. Furthermore, there is evidence of ongoing reduction in luminal calibre beyond 6-8 months post-intervention-the time point at which completion of vessel-wall healing was observed in the bare metal stent era. 30 The common thread linking both late stent thrombosis and late erosion of luminal calibre ('late luminal creep') seems to be the existence of a persistent inflammatory response at the coronary vessel-wall level following DES implantation. The most likely culprit appears to be the residual presence of permanent polymer following completion of its functional role. 4 -6,30 With the intention of developing a platform with optimal antirestenotic efficacy without obligate use of durable polymer, the ISAR stent development programme was conceived. We initially demonstrated that the incorporation of sand-blasted micropores into a 316L stainless steel backbone increased the capacitance of active-drug loading, resulting in an anti-restenotic efficacy superior to that of a thin-strut bare metal stent comparator and noninferior to that of the commercially available permanent polymer-paclitaxel-eluting stent (Taxus). 10 -12 However, when this platform was compared with the permanent-polymer sirolimus-eluting platform, we failed to show non-inferioritywhich seemed clearly related to the use of a superior comparator in the Cypher stent. 13 Options to further enhance the antirestenotic performance of an experimental platform include the inclusion of self-degrading, temporary polymer to delay activecompound elution and enhance efficacy, 13, 31, 32 Polymer-free dual drug-eluting stents the restenotic response cascade following stent-induced acute vessel trauma. Upon injury, endothelial cells express adhesion molecules that bind ligands on circulating monocytes, promoting their accumulation, transmigration, and subsequent elaboration of pro-inflammatory cytokines and vascular smooth muscle cell mitogens. Reactive oxygen species appear to be centrally involved in this response via enhancement of LDL oxidation, inhibition of nitric oxide release, and promotion of macrophage activation. 33 Probucol-a potent lipophilic antioxidant typically orally administered-has proved effective in inhibiting this restenotic response to balloon injury in both animal models and clinical trials. 16 -18 The mechanisms of benefit appear to involve inhibition of LDL oxidation, impairment of endothelial cell adhesion molecule . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... expression and macrophage-derived cytokine production, as well as a direct free-radical scavenging effect. 34 -36 To date, the benefits of probucol in preventing restenosis postballoon angioplasty have not been reliably replicated in the era of coronary stenting. 18,37 -39 In terms of the antirestenotic effect of probucol, it has been postulated that the prevention of constrictive remodelling may have been proportionally more important than its inhibition of neointimal hyperplasia. 40 In the current study, however, the extent of late luminal loss we observed with this novel Dual-DES platform is clearly superior to that observed with previous ISAR stent iterations. Although intravascular ultrasound follow-up was not a component of this current analysis, this is strongly suggestive of an important additional inhibition of neointimal hyperplasia. There are two possible explanations. It is conceivable that a stent-based delivery system resulted in enhanced local drug concentrations and effects. Indeed, the relatively narrow therapeutic index of oral probucol-consequent, perhaps, on the oral administration of a slowly accumulating liposoluble drug-has restrained its widespread use in clinical practice. 41 This issue is largely overcome by a tissue-specific stent delivery system. In support of a direct probucol-effect on the neointima, more recent evidence from experimental models suggests that probucol significantly improves re-endothelialization following stent implantation 42 -a feature which is strongly related to lower neointimal overgrowth (as well as attractive from a DES safety viewpoint). A second possibility is that the presence of probucol may have retarded the release of rapamycin, thereby enhancing its efficacy. It should be recognized that in utilizing a primary angiographic endpoint, the conclusions of our trial are based on incomplete observations: 82.2% follow-up in this current study. This is an inherent feature of all DES trials utilizing such an angiographic endpoint. In this regard, concordance of the results of the secondary endpoint analyses (including TLR)-for which data were available on all participants-is noteworthy. We acknowledge that routine angiographic follow-up increases the incidence of TLR in a manner that may not reflect real-life practice. However, this increases the sensitivity of a study to detect differences in restenosis between various devices. This trial was not powered to detect differences in rare clinical events, and clinical outcome data must be interpreted with this in mind. At present, clinical surveillance is available only for 1 year. Longer term registry follow-up for all patients is mandated regarding the occurrence of adverse events later than 1 year post-stenting.
In conclusion, we have shown that a novel rapamycin-and probucol-eluting Dual-DES is associated with a high anti-restenotic performance without recourse to a carrier polymer and that its efficacy is superior to that of the permanent polymer ZES platform and comparable with that of the permanent polymer SES platform. Although avoidance of durable polymer has interesting potential Dual-DES, rapamycin-and probucol-eluting stent; SES, sirolimus eluting stent; TLR, target lesion revascularization; ZES, zotarolimus-eluting stent.
Polymer-free dual drug-eluting stents long-term safety implications, durability of performance efficacy and accrual of postulated clinical benefit remain subject to future investigation. 
